


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently amended) A compound of formula I:



wherein:

the dotted line represents an optional bond;

**R<sup>1</sup>** and **R<sup>1'</sup>** are each independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>3-8</sub>-cycloalk(en)yl and cyano-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; or **R<sup>1</sup>** and **R<sup>1'</sup>** taken together with the carbon atom to which they are attached form a 3-8 membered saturated or unsaturated ring [[which]]that optionally contains 1 or 2 heteroatoms;

**s** is 0 or 1;

**U** is O, NR<sup>11</sup>, S, SO<sub>2</sub>, SO<sub>2</sub>NR<sup>11</sup>, CO-O or CO-NR<sup>11</sup>; wherein **R<sup>11</sup>** is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; or **R<sup>2</sup>** and **R<sup>11</sup>** taken together with the nitrogen atom to which they are attached

form a 4-8 membered saturated or unsaturated ring [[which]]that optionally contains 1, 2 or 3 further heteroatoms;

$R^2$  is selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar, Ar- $C_{1-6}$ -alk(en/yn)yl, Ar- $C_{3-8}$ -cycloalk(en)yl, Ar- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, acyl, hydroxy- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, halogen, halo- $C_{1-6}$ -alk(en/yn)yl, halo- $C_{3-8}$ -cycloalk(en)yl, halo- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, cyano, cyano- $C_{1-6}$ -alk(en/yn)yl, cyano- $C_{3-8}$ -cycloalk(en)yl, cyano- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl,  $-NO_2$ ,  $NR^{10}R^{10'}$ - $C_{1-6}$ -alk(en/yn)yl,  $NR^{10}R^{10'}$ - $C_{3-8}$ -cycloalk(en)yl and  $NR^{10}R^{10'}$ - $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl; wherein

$R^{10}$  and  $R^{10'}$  are each independently selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, halo- $C_{1-6}$ -alk(en/yn)yl, halo- $C_{3-8}$ -cycloalk(en)yl, halo- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, cyano- $C_{1-6}$ -alk(en/yn)yl, cyano- $C_{3-8}$ -cycloalk(en)yl and cyano- $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl[[,]]; or

$R^{10}$  and  $R^{10'}$  taken together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring [[which]]that optionally contains 1, 2 or 3 further heteroatoms;

with the proviso that when  $R^2$  is  $NO_2$ , halogen or cyano, then  $s$  is 0; and

with the proviso that when  $R^2$  is a hydrogen atom or acyl and  $s$  is 1, then  $U$  is  $NR^{11}$ , O or S;

wherein the group  $-(U)_sR^2$  is linked to position 4 or 6 of the indole or indoline;

$q$  is 0 or 1;

**Z** is O or S;

**X** is CO or SO<sub>2</sub>; with the proviso that **q** is 0 when **X** is SO<sub>2</sub>;

**R**<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, heterocycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yl-C<sub>3-8</sub>-cycloalk(en)yl, C<sub>1-6</sub>-alk(en/yn)yl-heterocycloalk(en)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, Ar-heterocycloalk(en)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl-C<sub>3-8</sub>-cycloalk(en)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl-heterocycloalk(en)yl, C<sub>1-6</sub>-alk(en/yn)yloxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yloxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yloxy-C<sub>3-8</sub>-cycloalk(en)yl, C<sub>1-6</sub>-alk(en/yn)yloxy-heterocycloalk(en)yl, Ar-oxy-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yloxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yloxy-carbonyl-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yloxy-carbonyl-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yloxy-carbonyl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-heterocycloalk(en)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl-heterocycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl, halo-heterocycloalk(en)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl-heterocycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl-Ar, halo-C<sub>3-8</sub>-cycloalk(en)yl-Ar, halo-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl-Ar, halo-C<sub>1-6</sub>-alk(en/yn)yl-C<sub>3-8</sub>-cycloalk(en)yl-Ar, cyano-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>3-8</sub>-cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>1-6</sub>-alk(en/yn)yl-C<sub>3-8</sub>-cycloalk(en)yl, cyano-C<sub>1-6</sub>-alk(en/yn)yl-heterocycloalk(en)yl, acyl-C<sub>1-6</sub>-alk(en/yn)yl, acyl-C<sub>3-8</sub>-cycloalk(en)yl, acyl-heterocycloalk(en)yl, acyl-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl-C<sub>1-6</sub>-alk(en/yn)yl-C<sub>3-8</sub>-cycloalk(en)yl, acyl-C<sub>1-6</sub>-alk(en/yn)yl-heterocycloalk(en)yl, [[ and ]]-NR<sup>12</sup>R<sup>12</sup>, optionally substituted NR<sup>12</sup>R<sup>12</sup>-C<sub>1-6</sub>-alk(en/yn)yl, optionally substituted NR<sup>12</sup>R<sup>12</sup>-C<sub>3-8</sub>-cycloalk(en)yl, and optionally substituted NR<sup>12</sup>R<sup>12</sup>-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; wherein

**R**<sup>12</sup> and **R**<sup>12</sup> are each independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-


alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>3-8</sub>-cycloalk(en)yl and cyano-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl[[,]], or

**R**<sup>12</sup> and **R**<sup>12'</sup> taken together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring [[which]]that optionally contains 1, 2 or 3 further heteroatoms;

with the proviso that when **R**<sup>3</sup> is NR<sup>12</sup>R<sup>12'</sup>, then q is 0;

and

Y represents a group of formula **II**, **III**, **IV**, **V**, **VI**, **XXX** or **XXXI**:



wherein:

**W** is O or S;

**T** is N, NH or O;

**L** is N, C or CH;

**a** is 0, 1, 2 or 3;

**b** is 0, 1, 2, 3 or 4;

**c** is 0 or 1;

**d** is 0, 1, 2 or 3;

**e** is 0, 1 or 2;

**f** is 0, 1, 2, 3, 4 or 5;

**g** is 0, 1, 2, 3 or 4;

**h** is 0, 1, 2 or 3;

**j** is 0, 1, 2 or 3; with the proviso that when **T** is a nitrogen atom, then **j** is 0, 1, 2 or 3; and  
when **T** is NH or an oxygen atom then **j** is 0, 1 or 2;

**k** is 0, 1, 2, 3 or 4; and

each **R**<sup>5</sup> is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-thio, Ar-oxo, acyl, C<sub>1-6</sub>-alk(en/yn)yloxy, C<sub>3-8</sub>-cycloalk(en)yloxy, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yloxy, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, -CO-NR<sup>6</sup>R<sup>6</sup>, cyano, cyano-C<sub>1-6</sub>-alk(en/yn)yl, cyano-C<sub>3-8</sub>-cycloalk(en)yl, cyano-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, -NR<sup>7</sup>R<sup>7</sup>, -S-R<sup>8</sup> and -

$\text{SO}_2\text{R}^8$  [1,]); or two adjacent  $\text{R}^5$  groups taken together with the aromatic group to which they are attached form a 4-8 membered ring [[which]] that optionally contains one or two heteroatoms; wherein:

$\text{R}^6$  and  $\text{R}^6'$  are each independently selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl and Ar;

$\text{R}^7$  and  $\text{R}^7'$  are each independently selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl, Ar and acyl;

and

$\text{R}^8$  is selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl, Ar and  $-\text{NR}^9\text{R}^9'$ ; wherein:

$\text{R}^9$  and  $\text{R}^9'$  are each independently selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl and  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl; provided that when  $\text{R}^8$  is  $-\text{NR}^9\text{R}^9'$ ; then  $\text{R}^5$  is not  $-\text{S-}\text{R}^8$ ;

or salts thereof;

with the proviso that the compound of formula I is not:

N-[1-(phenylmethyl)-1H-indol-5-yl]-Methanesulfonamide;

N-[1-[(4-fluorophenyl)methyl]-1H-indol-5-yl]-Methanesulfonamide;

N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-Methanesulfonamide;

N-[1-(phenylmethyl)-1H-indol-5-yl]-N'-4-quinolinyl-Urea;

N-[1-(phenylmethyl)-1H-indol-5-yl]-N'-4-quinolinyl-Urea; or

1-(1-benzyl-5-indolinyl)-3-phenyl-Urea;

or salts thereof.

2. (Original) A compound according to Claim 1, wherein at least one of  $\mathbf{R}^1$  or  $\mathbf{R}^1'$  is a hydrogen atom.
3. (Previously presented) A compound according to claim 2, wherein both  $\mathbf{R}^1$  and  $\mathbf{R}^1'$  are hydrogen atoms.
4. (Previously presented) A compound according to claim 1, wherein  $s$  is 0.
5. (Previously presented) A compound according to claim 1, wherein  $s$  is 1.
6. (Previously presented) A compound according to claim 1, wherein  $\mathbf{R}^2$  is a hydrogen atom.
7. (Previously presented) A compound according to claim 1, wherein  $\mathbf{R}^2$  is  $\text{NO}_2$  or a halogen atom.
8. (Previously presented) A compound according to claim 1, wherein  $\mathbf{U}$  is  $\text{NR}^{11}$ .
9. (Currently Amended) A compound according to [[Claim]]claim 8, wherein  $\mathbf{R}^{11}$  is a hydrogen atom.
10. (Previously presented) A compound according to claim 1, wherein  $\mathbf{X}$  is  $\text{CO}$ .
11. (Previously presented) A compound according to claim 1, wherein  $\mathbf{X}$  is  $\text{SO}_2$ .
12. (Previously presented) A compound according to claim 1, wherein  $\mathbf{q}$  is 0.
13. (Previously presented) A compound according to claim 1, wherein  $\mathbf{q}$  is 1.
14. (Currently amended) A compound according to [[Claim]]claim 13, wherein  $\mathbf{Z}$  is an oxygen atom.
15. (Currently amended) A compound according to claim 1, wherein  $\mathbf{R}^3$  is selected from the group consisting of  $\text{C}_{1-6}\text{-alk(en/yn)yl}$ ,  $\text{C}_{3-8}\text{-cycloalk(en)yl}$ ,  $\text{Ar}$ ,  $\text{Ar-C}_{1-6}\text{-alk(en/yn)yl}$ ,  $\text{Ar-oxy-C}_{1-6}\text{-alk(en/yn)yl}$ ,  $\text{Ar-C}_{1-6}\text{-alk(en/yn)yloxy-C}_{1-6}\text{-alk(en/yn)yl}$  and  $-\text{NR}^{12}\mathbf{R}^{12'}$ ; with the proviso that when  $\mathbf{R}^3$  is  $\text{NR}^{12}\mathbf{R}^{12'}$ , then  $\mathbf{q}$  is 0.
16. (Currently amended) A compound according to [[Claim]]claim 15, wherein  $\mathbf{R}^3$  is  $\text{NR}^{12}\mathbf{R}^{12'}$ ,  $\mathbf{q}$  is 0 and  $\mathbf{R}^{12}$  and  $\mathbf{R}^{12'}$  are each independently selected from the group consisting of hydrogen,  $\text{C}_{1-6}\text{-alk(en/yn)yl}$ ,  $\text{Ar}$  and  $\text{Ar-C}_{1-6}\text{-alk(en/yn)yl}[[,]]$ ; or  $\mathbf{R}^{12}$  and  $\mathbf{R}^{12'}$  taken together

with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring [[which]]that optionally contains 1, 2 or 3 further heteroatoms.

17. (Previously presented) A compound according to claim 1, wherein **Y** is of formula **II**, **III**, **V**, **XXX**, or **XXXI**.
18. (Previously presented) A compound according to claim 17, wherein **Y** is of formula **II** or **III** and **W** is a sulphur atom.
19. (Previously presented) A compound according to claim 17, wherein **Y** is of formula **XXX** and **T** is a nitrogen atom or an oxygen atom.
20. (Previously presented) A compound according to claim 17, wherein **Y** is of formula **XXXI** and **L** is C or CH.
21. (Currently amended) A compound according to claim 1, wherein each **R**<sup>5</sup> is independently selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-thio, Ar-oxy, halogen and halo-C<sub>1-6</sub>-alk(en/yn)yl; or two adjacent **R**<sup>5</sup> taken together with the aromatic group to which they are attached form a 4-8 membered ring [[which]]that optionally contains one or two heteroatoms.
22. (Currently amended) A compound selected from the group consisting of:  
N-[4-Chloro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;  
N-[4-Chloro-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;  
[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid propyl ester[[;]];  
N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-C-phenyl-methanesulfonamide[[;]];  
4-Fluoro-N-[1-(4-fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-benzamide[[;]];  
N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide[[;]];  
N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-thiophen-2-ylacetamide[[;]]

N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide[;;];  
3-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-1,1-diisopropylurea[;;];  
Morpholine-4-carboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide[;;];  
Pyrrolidine-1-carboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide[;;];  
[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid 2-benzyloxyethyl ester[;;];  
3-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-1-methyl-1-propylurea[;;];  
[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid tert-butyl ester[;;];  
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-C-phenyl-methanesulfonamide[;;];  
Butane-1-sulfonic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide[;;];  
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-4-fluorobenzamide[;;];  
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide[;;];  
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-phenoxyacetamide[;;];  
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide[;;];  
N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide[;;];  
Cyclopentanecarboxylic acid [1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-amide[;;];

N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-thiophen-2-ylacetamide[;;];

N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-isonicotinamide[;;];

N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-4-dimethylaminobenzamide[;;];

N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide[;;];

N-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-6-trifluoromethylnicotinamide[;;];

1-tert-Butyl-3-[1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-urea[;;];

1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-ethylurea[;;];

1-Benzyl-3-[1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-urea[;;];

1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-phenethylurea[;;];

1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-thiophen-2-ylurea[;;];

1-[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3-thiophen-3-ylurea[;;];

[1-(5-Chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid propyl ester;

2,2-Dimethyl-N-[6-nitro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-propionamide[;;];

N-[1-(5-Chlorothiophen-2-ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide[;;];

2-(4-Fluorophenyl)-N-[6-nitro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide[;;];

N-[1-(5-Chlorothiophen-2-ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

N-[1-(5-Chlorothiophen-2-ylmethyl)-6-nitro-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[6-Amino-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide[;;];

N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide; [;;];

N-[6-Amino-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2,2-dimethylpropionamide[;;];

N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide[;;];

N-[6-Amino-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[6-Amino-1-(4-fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[6-Amino-1-(3-fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(5-Chlorothiophen-2-ylmethyl)-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[6-Bromo-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[6-Bromo-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(4-Chlorobenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-[1-(4-Isopropylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(3-Fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(6-Chlorobenzo[1,3]dioxol-5-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-[1-(2-Chloro-5-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

N-{1-[5-(4-Chlorophenoxy)-1,3-dimethyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(6-p-tolyloxy-pyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-{1-[6-(4-Chlorophenylsulfanyl)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-3,3-dimethylbutyramide;

N-{1-[6-(4-Cyanophenoxy)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(6-trifluoromethylpyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

3,3-Dimethyl-N-[1-(3-methyl-benzo[b]thiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-[1-(6-Fluoro-4H-benzo[1,3]dioxin-8-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(6-phenoxyppyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

3,3-Dimethyl-N-[1-(3-methyl-5-phenyl-isoxazol-4-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-(1-Benzo[b]thiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl)-3,3-dimethylbutyramide;

N-{1-[1-(4-Fluorophenyl)-5-methyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-3,3-dimethylbutyramide;

3,3-Dimethyl-N-[1-(5-methylthiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

3,3-Dimethyl-N-[1-(4-pyrrol-1-yl-benzyl)-2,3-dihydro-1H-indol-5-yl]-butyramide;

N-[1-(4-Chlorobenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

2-(4-Fluorophenyl)-N-[1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;

2-(4-Fluorophenyl)-N-[1-(4-isopropylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;

2-(4-Fluorophenyl)-N-[1-(3-fluoro-4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;

N-[1-(6-Chlorobenzo[1,3]dioxol-5-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

N-[1-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

N-[1-(2-Chloro-5-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

N-[1-[5-(4-Chlorophenoxy)-1,3-dimethyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

N-[1-[6-(4-Cyanophenoxy)-pyridin-3-ylmethyl]-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

2-(4-Fluorophenyl)-N-[1-(3-methyl-benzo[b]thiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;

N-[1-(6-Fluoro-4H-benzo[1,3]dioxin-8-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

2-(4-Fluorophenyl)-N-[1-(6-phenoxy-pyridin-3-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-acetamide;

N-(1-Benzo[b]thiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-2-(4-fluorophenyl)-acetamide;

2-(4-Fluorophenyl)-N-{1-[1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-5-yl}-acetamide;

2-(4-Fluorophenyl)-N-[1-(5-methylthiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]-acetamide; and

2-(4-Fluorophenyl)-N-[1-(4-pyrrol-1-yl-benzyl)-2,3-dihydro-1H-indol-5-yl]-acetamide[.,.];

or

a pharmaceutically acceptable salt thereof.

23. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable carriers or diluents.

24-37. (Withdrawn).